Immune dysregulation and system pathology in COVID-19

References

• Sarzi-Puttini P, Giorgi V, Sirotti S, et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol. 2020;38(2):337–342.
   PubMed Web of Science ®Google Scholar
• Song P, Karako T. COVID-19: Real-time dissemination of scientific information to fight a public health emergency of international concern. Biosci Trends. 2020;14(1):1–2.
   Web of Science ®Google Scholar
• Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91(1):157–160.
   PubMedGoogle Scholar
• Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med. 2020; 382(13):1199–1207.
   Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020; 395(10223):514–523.
   PubMed Web of Science ®Google Scholar
• Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. Jama. 2020; 323(15):1488.
   Web of Science ®Google Scholar
• Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020; 71(15):762–768.
   Web of Science ®Google Scholar
• Kahn JS, McIntosh K. History and recent advances in coronavirus discovery. Pediatr Infect Dis J. 2005;24(11):S223–S227.
   PubMedGoogle Scholar
• Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727–733.
   Web of Science ®Google Scholar
• Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579(7798):265–269.
   PubMed Web of Science ®Google Scholar
• Woo PC, Huang Y, Lau SKP, et al. Coronavirus genomics and bioinformatics analysis. viruses. 2010; 2(8):1804–1820.
   PubMed Web of Science ®Google Scholar
• Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1–23.
   PubMedGoogle Scholar
• Phan T. Novel coronavirus: From discovery to clinical diagnostics. Infect Genet Evol. 2020;79:104211.
   PubMed Web of Science ®Google Scholar
• Snijder EJ, Bredenbeek PJ, Dobbe JC, et al. Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J Mol Biol. 2003; 331(5):991–1004.
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020; 27(6):992–1000.e3.
   PubMed Web of Science ®Google Scholar
• Phan T. Genetic diversity and evolution of SARS-CoV-2. Infect Genet Evol. 2020;81:104260.
   PubMed Web of Science ®Google Scholar
• Angeletti S, Benvenuto D, Bianchi M, et al. COVID‐2019: The role of the nsp2 and nsp3 in its pathogenesis. J Med Virol. 2020; 92(6):584–588.
   Web of Science ®Google Scholar
• Liu Y, Gayle AA, Wilder-Smith A, et al. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. 2020;27(2):taaa021.
   Web of Science ®Google Scholar
• Wang L, Wang Y, Ye D, et al. A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence. Int J Antimicrob Agents. 2020; 55(6):105948.
   PubMed Web of Science ®Google Scholar
• Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565–574.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 181(2):271–280.e8.
   Web of Science ®Google Scholar
• Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270–273.
   PubMed Web of Science ®Google Scholar
• Coutard B, Valle C, De Lamballerie X, et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020;176:104742.
   PubMed Web of Science ®Google Scholar
• Wu C, Zheng M, Yang Y, et al. Furin: A potential therapeutic target for COVID-19. Iscience. 2020; 23(10):101642.
   PubMed Web of Science ®Google Scholar
• Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4):420–422.
   PubMed Web of Science ®Google Scholar
• Mingkai Tan, Yanxia Liu, Ruiping Zhou, et al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China.
   Google Scholar
• Diao B, Wang C, Tan Y, et al. Reduction and functional exhaustion of T cells in patients with Coronavirus Disease 2019 (COVID-19). Front Immunol. 2020; 11(827): DOI:10.3389/fimmu.2020.00827
   Google Scholar
• Liu Y, Liao W, Wan L, et al. Correlation between relative nasopharyngeal virus RNA load and lymphocyte count disease severity in patients with COVID-19. Viral Immunol. 2020; DOI:10.1089/vim.2020.0062
   Web of Science ®Google Scholar
• Guan W, Xian J. The progress of 2019 Novel Coronavirus (2019‐nCoV) event in China. J Med Virol. 2020.
   Web of Science ®Google Scholar
• Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020; 130(5):2620–2629.
   Web of Science ®Google Scholar
• Liao M, et al. The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing2020.
   Google Scholar
• Zhang B, Zhou X, Zhu C, et al. Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19. Front Mol Biosci. 2020;7:157.
   Google Scholar
• Rokni M, Ahmadikia K, Asghari S, et al. Comparison of clinical, para-clinical and laboratory findings in survived and deceased patients with COVID-19: Diagnostic role of inflammatory indications in determining the severity of illness. BMC Infect Dis. 2020; 20(1):1–11.
   Web of Science ®Google Scholar
• Wang J, Li Q, Yin Y, et al. Excessive neutrophils and neutrophil extracellular traps in COVID-19. Front Immunol. 2020;11:2063.
   PubMed Web of Science ®Google Scholar
• Khartabil TA, Russcher H, van der Ven A, et al. A summary of the diagnostic and prognostic value of hemocytometry markers in COVID-19 patients. Crit Rev Clin Lab Sci. 2020; 57(6):415–431.
   PubMed Web of Science ®Google Scholar
• Wang F, Nie J, Wang H, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis. 2020; 221(11):1762–1769.
   Web of Science ®Google Scholar
• Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020; 11(2):216–228.
   PubMed Web of Science ®Google Scholar
• Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. 2020;53(3):368–370.
   Google Scholar
• Hotez PJ, Bottazzi ME, Corry DB. The potential role of Th17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancement. Microbes Infect. 2020;22(4–5):165–167.
   Web of Science ®Google Scholar
• Ouyang Y, Yin J, Wang W, et al. Down-regulated gene expression spectrum and immune responses changed during the disease progression in COVID-19 patients. Clin Infect Dis. 2020; 71(16):2052–2060.
   Web of Science ®Google Scholar
• Zheng H-Y, Zhang M, Yang C-X, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. 2020; 17(5):541–543.
   PubMed Web of Science ®Google Scholar
• Chen X, Ling J, Mo P, et al. Restoration of leukomonocyte counts is associated with viral clearance in COVID-19 hospitalized patients. MedRxiv.  2020.03.03.20030437
   Google Scholar
• Zheng M, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533-535.
   Web of Science ®Google Scholar
• Liu B, Han J, Cheng X, et al. Persistent SARS-CoV-2 presence is companied with defects in adaptive immune system in non-severe COVID-19 patients. medRxiv. 2020.03.26.20044768
   Google Scholar
• Bertram S, Heurich A, Lavender H, et al. Influenza and SARS-Coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts. Plos One. 2012; 7(4):e35876.
   PubMed Web of Science ®Google Scholar
• Kovacs A, Ipsen A, Manzel A, et al. ACE2 drives dendritic cell function and neuroantigen specific immune responses. Brain Behav Immun. 2013;29:S19.
   Google Scholar
• Wang K, Chen W, Zhou Y-S, et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. bioRxiv. 2020:2020.03.14.988345.
   Google Scholar
• Woodhead VE, Binks MH, Chain BM, et al. From sentinel to messenger: an extended phenotypic analysis of the monocyte to dendritic cell transition. Immunology. 1998; 94(4):552–559.
   PubMed Web of Science ®Google Scholar
• Cai G, Cui X, Zhu X, et al. A hint on the COVID-19 risk: population disparities in gene expression of three receptors of SARS-CoV. 2020;
   Google Scholar
• Cervantes-Barragán L, Kalinke U, Züst R, et al. Type I IFN-mediated protection of macrophages and dendritic cells secures control of murine coronavirus infection. J Immunol. 2009; 182(2):1099–1106.
   PubMed Web of Science ®Google Scholar
• Thevarajan I, Nguyen THO, Koutsakos M, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med. 2020; 26(4):453–455.
   PubMed Web of Science ®Google Scholar
• Hosszu KK, Santiago-Schwarz F, Peerschke EIB, et al. Evidence that a C1q/C1qR system regulates monocyte-derived dendritic cell differentiation at the interface of innate and acquired immunity. Innate Immun. 2010; 16(2):115–127.
   PubMed Web of Science ®Google Scholar
• MacDonald KPA, Munster DJ, Clark GJ, et al. Characterization of human blood dendritic cell subsets. Blood. 2002; 100(13):4512–4520.
   PubMed Web of Science ®Google Scholar
• Zhu N, Zhang D, Wang W, et al. A novel Coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727–733.
   PubMed Web of Science ®Google Scholar
• Rescigno M, Winzler C, Delia D, et al. Dendritic cell maturation is required for initiation of the immune response. J Leukoc Biol. 1997; 61(4):415–421.
   PubMed Web of Science ®Google Scholar
• Zhou J, Chu H, Li C, et al. Active replication of middle east respiratory syndrome Coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: Implications for pathogenesis. J Infect Dis. 2014; 209(9):1331–1342.
   PubMed Web of Science ®Google Scholar
• Chu H, Chan JF-W, Wang Y, et al. Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19. Clin Infect Dis. 2020; 71(6):1400–1409.
   Web of Science ®Google Scholar
• Zhou R, To KK-W, Wong Y-C, et al. Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses. Immunity. 2020; 53(4):864–877. e5
   PubMed Web of Science ®Google Scholar
• Yang D, Chu H, Hou Y, et al. Attenuated interferon and proinflammatory response in SARS-CoV-2–infected human dendritic cells is associated with viral antagonism of STAT1 phosphorylation. J Infect Dis. 2020; 222(5):734–745.
   PubMed Web of Science ®Google Scholar
• Blanco-Melo D, Nilsson-Payant BE, Liu W-C, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020; 181(5):1036–1045.e9.
   PubMed Web of Science ®Google Scholar
• Hume DA, Irvine KM, Pridans C. The mononuclear phagocyte system: The relationship between monocytes and macrophages. Trends Immunol. 2019;40(2):98–112.
   PubMed Web of Science ®Google Scholar
• Nikitina E, Larionova I, Choinzonov E, et al. Monocytes and macrophages as viral targets and reservoirs. Int J Mol Sci. 2018; 19(9):2821.
   PubMed Web of Science ®Google Scholar
• Jafarzadeh A, Larussa T, Nemati M, et al. T cell subsets play an important role in the determination of the clinical outcome of Helicobacter pylori infection. Microb Pathog. 2018;116:227–236.
   PubMed Web of Science ®Google Scholar
• Dandekar AA, Perlman S. Immunopathogenesis of coronavirus infections: implications for SARS. Nat Rev Immunol. 2005;5(12):917–927.
   PubMed Web of Science ®Google Scholar
• Acharya D, Liu G, Gack MU. Dysregulation of type I interferon responses in COVID-19. Nat Rev Immunol. 2020;20(7):397–398.
   PubMed Web of Science ®Google Scholar
• Zhang D, Guo R, Lei L, et al. Frontline Science:COVID‐19 infection induces readily detectable morphologic and inflammation‐related phenotypic changes in peripheral blood monocytes. J Leukoc Biol. 2021 ;109(1):13-22.
   Web of Science ®Google Scholar
• Fung S-Y, Yuen K-S, Ye Z-W, et al. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses. Emerg Microbes Infect. 2020; 9(1):558–570.
   PubMed Web of Science ®Google Scholar
• X H Yao, T Y Li, Z C He, et al. A pathological report of three COVID-19 cases by minimally invasive autopsies. Zhonghua Bing Li Xue Za Zhi= Chinese Journal of Pathology. 2020;49:E009–E009.
   Google Scholar
• Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Fu B, Zheng X, et al. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Natl Sci Rev. 2020;
   PubMed Web of Science ®Google Scholar
• Zhou Y, Fu B, Zheng X, et al. Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+ CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. BioRxiv. 2020;
   Google Scholar
• Schulte-Schrepping J, Reusch N, Paclik D, et al. Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell. 2020; 182(6):1419–1440. e23.
   PubMed Web of Science ®Google Scholar
• Yang Y, Peng F, Wang R, et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun. 2020;109:102434.
   PubMed Web of Science ®Google Scholar
• Chen I-Y, Moriyama M, Chang M-F, et al. Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. Front Microbiol. 2019;10:50.
   PubMed Web of Science ®Google Scholar
• Sun S, Zhao G, Liu C, et al. Inhibition of complement activation alleviates acute lung injury induced by highly pathogenic avian influenza H5N1 virus infection. Am J Respir Cell Mol Biol. 2013; 49(2):221–230.
   PubMed Web of Science ®Google Scholar
• Gao T, Koh Y, Foote MB, et al. Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. MedRxiv. 2020; DOI:10.1101/2020.11.25.20233163
   Google Scholar
• Cugno M, Meroni PL, Gualtierotti R, et al. Complement activation in patients with COVID-19: A novel therapeutic target. J Allergy Clin Immunol. 2020; 146(1):215–217.
   PubMed Web of Science ®Google Scholar
• Gralinski LE, Sheahan TP, Morrison TE, et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. MBio. 2018; 9(5):
   PubMed Web of Science ®Google Scholar
• Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res. 2020;220:1–13.
   PubMed Web of Science ®Google Scholar
• Escher R, Breakey N, Lämmle B. Severe COVID-19 infection associated with endothelial activation. Thromb Res. 2020;190:62.
   PubMed Web of Science ®Google Scholar
• Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID‐19 patients in intensive care unit. A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020; 18(7):1738–1742.
   PubMed Web of Science ®Google Scholar
• Kamitaki N, Sekar A, Handsaker RE, et al. Complement genes contribute sex-biased vulnerability in diverse disorders. Nature. 2020;582(7813):577–581.
   Web of Science ®Google Scholar
• Yu H, Li D, Deng Z, et al. Total protein as a biomarker for predicting coronavirus disease-2019 pneumonia. SSRN Electronic J 2020; DOI:10.2139/ssrn.3551289
   PubMedGoogle Scholar
• Du Y, Tu L, Zhu P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study. Am J Respir Crit Care Med. 2020; 201(11):1372–1379.
   PubMed Web of Science ®Google Scholar
• Li Q, Ding X, Xia G, et al. A simple laboratory parameter facilitates early identification of COVID-19 patients. MedRxiv. 2020;
   Google Scholar
• Zhang J-J, Dong X, Cao -Y-Y, et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy. 2020; 75(7):1730–1741.
   Web of Science ®Google Scholar
• Xie G, Ding F, Han L, et al. The role of peripheral blood eosinophil counts in COVID‐19 patients. Allergy. 2020; 76(2):471–482.
   Web of Science ®Google Scholar
• Bass DA. Behavior of eosinophil leukocytes in acute inflammation. II. Eosinophil dynamics during acute inflammation. J Clin Invest. 1975;56(4):870–879.
   PubMed Web of Science ®Google Scholar
• Hassani M, Leijte G, Bruse N, et al. Differentiation and activation of eosinophils in the human bone marrow during experimental human endotoxemia. J Leukoc Biol. 2020; 108(5):1665–1671.
   PubMed Web of Science ®Google Scholar
• Butterfield JH. Treatment of hypereosinophilic syndromes with prednisone, hydroxyurea, and interferon. Immunol Allergy Clin North Am. 2007;27(3):493–518.
   PubMed Web of Science ®Google Scholar
• Lindsley AW, Schwartz JT, Rothenberg ME. Eosinophil responses during COVID-19 infections and coronavirus vaccination. J Allergy Clin Immunol. 2020;146(1):1–7.
   Web of Science ®Google Scholar
• Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473–474.
   PubMed Web of Science ®Google Scholar
• Li H,  Xiang X, Ren H, et al. SAA is a biomarker to distinguish the severity and prognosis of Coronavirus Disease 2019 (COVID-19). J Infect. 2020;80(6): 646–655.
   Google Scholar
• Wang Y, Zhou F, Zhang D, et al. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: Study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial. Trials. 2020;21(1):422.
   PubMed Web of Science ®Google Scholar
• Liu J, Liu Y, Xiang P, et al. Neutrophil-to-lymphocyte ratio predicts severe illness patients with 2019 novel coronavirus in the early stage. MedRxiv. 2020;
   Google Scholar
• Yao X, Li T, He Z, et al. A pathological report of three COVID-19 cases by minimally invasive autopsies. Zhonghua bing li xue za zhi= Chinese journal of pathology 2020; 49:E009–E.
   Google Scholar
• Fox SE, Akmatbekov A, Harbert JL, et al. Pulmonary and cardiac pathology in Covid-19: The first autopsy series from New Orleans. medRxiv. 2020
   Google Scholar
• Barnes BJ, Adrover JM, Baxter-Stoltzfus A, et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J Exp Med. 2020; 217(6): DOI:10.1084/jem.20200652
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Targeting the pathogenic role of interleukin 1{beta} in the progression of smoldering/indolent myeloma to active disease. Mayo Clin Proc. 2009;84(2):105–107.
   PubMed Web of Science ®Google Scholar
• Mehta P, McAuley DF, Brown M, et al. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395(10229):1033–1034.
   PubMed Web of Science ®Google Scholar
• Tang X, Wu C, Li X, et al. On the origin and continuing evolution of SARS-CoV-2. Natl Sci Rev. 2020; 7(6):1012–1023.
   Web of Science ®Google Scholar
• Huang K-J, Su I-J, Theron M, et al. An interferon-gamma-related cytokine storm in SARS patients. J Med Virol. 2005; 75(2):185–194.
   PubMed Web of Science ®Google Scholar
• Zhou G, Chen S, Chen Z. Advances in COVID-19: The virus, the pathogenesis, and evidence-based control and therapeutic strategies. Front Med. 2020.
   Web of Science ®Google Scholar
• Song C-Y,  Xu J, He J-Q, et al. COVID-19 early warning score: A multi-parameter screening tool to identify highly suspected patients. 2020.
   Google Scholar
• Yu L, Tong Y, Shen G, et al. Immunodepletion with hypoxemia: A potential high risk subtype of Coronavirus Disease 2019. 2020
   Google Scholar
• Gasteiger G, Fan X, Dikiy S, et al. Tissue residency of innate lymphoid cells in lymphoid and non-lymphoid organs. Science. 2015; 350(6263):981–985.
   PubMed Web of Science ®Google Scholar
• Marquardt N, Kekäläinen E, Chen P, et al. Human lung natural killer cells are predominantly comprised of highly differentiated hypofunctional CD69CD56 cells. J Allergy Clin Immunol. 2017; 139(4):1321–1330.e4.
   PubMed Web of Science ®Google Scholar
• Carlin LE, Hemann EA, Zacharias ZR, et al. Natural killer cell recruitment to the lung during influenza a virus infection is dependent on CXCR3, CCR5, and virus exposure dose, and virus exposure dose. Front Immunol. 2018;9:781.
   PubMed Web of Science ®Google Scholar
• Chu H, Chan JF-W, Wang Y, et al. Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19. Clin Infect Dis. 2020; 71(6):1400–1409.
   Web of Science ®Google Scholar
• Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020; 26(7):1033–1036.
   Web of Science ®Google Scholar
• Holle T, Moody M. Influenza and antibody-dependent cellular cytotoxicity. Front Immunol. 2019;10.
   Web of Science ®Google Scholar
• Merad M, Martin J. Pathological inflammation in patients with COVID-19: A key role for monocytes and macrophages. Nat Rev Immunol. 2020;20(1):1–8.
   PubMedGoogle Scholar
• Pinto D, Park YJ, Beltramello M, et al. Structural and functional analysis of a potent sarbecovirus neutralizing antibody. bioRxiv. 2020
   Google Scholar
• Tian S, Hu W, Niu L, et al. Pulmonary Pathology of Early-Phase Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer. J Thorac Oncol. 2020;15(5):700–704
   Google Scholar
• Wen W, Tang M, Liu Q, et al. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. Cell Discov. 2020; 6(1):1–18.
   PubMed Web of Science ®Google Scholar
• Huang H, Wang S, Jiang T, et al. High levels of circulating GM-CSF+CD4+ T cells are predictive of poor outcomes in sepsis patients: A prospective cohort study. Cell Mol Immunol. 2019; 16(6):602–610.
   PubMed Web of Science ®Google Scholar
• Walter JM, Helmin KA, Abdala-Valencia H, et al. Multidimensional assessment of alveolar T cells in critically ill patients. JCI Insight. 2018; 3(17): DOI:10.1172/jci.insight.123287
   Web of Science ®Google Scholar
• Fajnzylber J, Regan J, Coxen K, et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun. 2020; 11(1):1–9.
   PubMed Web of Science ®Google Scholar
• Chang D, Zhao P, Zhang D, et al. Persistent viral presence determines the clinical course of the disease in COVID-19. J Allergy Clin Immunol. 2020; 8(8):2585–2591. e1.
   Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama. 2020; 323(11):1061–1069.
   PubMed Web of Science ®Google Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020; 395(10223):507–513.
   PubMed Web of Science ®Google Scholar
• Tian S,  Xiong Y, Liu H, et al. Pathological study of the 2019 novel coronavirus disease (COVID-19) through post-mortem core biopsies. 2020;
   Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020; 395(10229):1054–1062.
   Web of Science ®Google Scholar
• Zeng J-H,  Liu Y-X, Yuan J, et al. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. Infection. 2020;1.
   Web of Science ®Google Scholar
• Edwards S, Small JD, Geratz JD, et al. An experimental model for myocarditis and congestive heart failure after rabbit coronavirus infection. The Journal of Infectious Diseases. 1992; 165(1):134–140.
   PubMed Web of Science ®Google Scholar
• Mendoza-Torres E, Oyarzún A, Mondaca-Ruff D, et al. ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension. Ther Adv Cardiovasc Dis. 2015; 9(4):217–237.
   PubMedGoogle Scholar
• Gallagher PE, Ferrario CM, Tallant EA. Regulation of ACE2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol. 2008;295(6):H2373–H2379.
   PubMed Web of Science ®Google Scholar
• Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382(18):1708–1720.
   Web of Science ®Google Scholar
• Zhang C, Shi L, Wang F-S. Liver injury in COVID-19: Management and challenges. The Lancet Gastroenterology & Hepatology. 2020;5(5):428–430.
   PubMed Web of Science ®Google Scholar
• Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: A descriptive study. The Lancet Infectious Diseases. 2020; 20(4):425–434.
   PubMed Web of Science ®Google Scholar
• Adams DH, Hubscher SG. Systemic viral infections and collateral damage in the liver. Am J Pathol. 2006;168(4):1057–1059.
   PubMed Web of Science ®Google Scholar
• Bangash MN, Patel J, Parekh D. COVID-19 and the liver: Little cause for concern. The Lancet Gastroenterology & Hepatology. 2020;5(6):529–530.
   PubMed Web of Science ®Google Scholar
• Chai X, Hu L, Zhang Y, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv. 2020;
   Google Scholar
• Banales JM, Huebert RC, Karlsen T, et al. Cholangiocyte pathobiology. Nat Clin Pract Gastroenterol Hepatol. 2019;16(5):269–281.
   Google Scholar
• Zhang W, Du R-H, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020; 9(1):386–389.
   PubMed Web of Science ®Google Scholar
• Xu Y, Li X, Zhu B, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med. 2020; 26(4):502–505.
   PubMed Web of Science ®Google Scholar
• Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel Coronavirus in the United States. N Engl J Med. 2020; 382(10):929–936.
   PubMed Web of Science ®Google Scholar
• Tang A, et al. Detection of Novel Coronavirus by RT-PCR in stool specimen from asymptomatic child, China. Emerg Infect Dis. 2020; 26(17):1337–1339.
   Google Scholar
• Lee JJ, Kopetz S, Vilar E, et al. Relative abundance of SARS-CoV-2 entry genes in the enterocytes of the lower gastrointestinal tract. bioRxiv. 2020;
   Google Scholar
• Harmer D, Gilbert M, Borman R, et al. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett. 2002; 532(1–2):107–110.
   PubMed Web of Science ®Google Scholar
• Yan R, Zhang Y, Guo Y, et al. Structural basis for the recognition of the 2019-nCoV by human ACE2. bioRxiv. 2020;
   Google Scholar
• Xiao F, Tang M, Zheng X, et al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020; 158(6):1831–1833.e3.
   Web of Science ®Google Scholar
• Yang Z, Shi J, He Z, et al. Predictors for imaging progression on chest CT from coronavirus disease 2019 (COVID-19) patients. Aging (Albany NY). 2020; 12(7):6037–6048.
   PubMedGoogle Scholar
• Mao L, Wang M, Chen S, et al. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: A retrospective case series study. SSRN Electronic J 2020; DOI:10.2139/ssrn.3544840
   PubMedGoogle Scholar
• Moriguchi T, Harii N, Goto J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis. 2020;94:55–58.
   PubMed Web of Science ®Google Scholar
• Palasca O, Santos A, Stolte C, et al. TISSUES 2.0: an integrative web resource on mammalian tissue expression. Database. 2018;
   Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 181(2):271–280.e8.
   Web of Science ®Google Scholar
• Baig AM, Khaleeq A, Ali U, et al. Evidence of the COVID-19 virus targeting the CNS: Tissue distribution, host-virus interaction, and proposed neurotropic mechanisms.ACS Chem Neurosci. 2020; 11(7):995–998.
   PubMed Web of Science ®Google Scholar
• Li Y-C, Bai W-Z, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020;92(6):552–555.
   Web of Science ®Google Scholar
• Glass WG, Subbarao K, Murphy B, et al. Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J Immunol (Baltimore, Md: 1950). 2004; 173(6):4030–4039.
   Google Scholar
• Ahmad I, Mui E, Galbraith L, et al. Sleeping Beauty screen reveals Pparg activation in metastatic prostate cancer. Proc Natl Acad Sci U S A. 2016; 113(29):8290–8295.
   PubMed Web of Science ®Google Scholar
• Li Y-C, Bai W-Z, Hirano N, et al. Coronavirus infection of rat dorsal root ganglia: ultrastructural characterization of viral replication, transfer, and the early response of satellite cells. Virus Res. 2012; 163(2):628–635.
   PubMed Web of Science ®Google Scholar
• Li Y-C, Bai W-Z, Hirano N, et al. Neurotropic virus tracing suggests a membranous-coating-mediated mechanism for transsynaptic communication. J Comp Neurol. 2013; 521(1):203–212.
   PubMed Web of Science ®Google Scholar
• Matsuda K, Park CH, Sunden Y, et al. The vagus nerve is one route of transneural invasion for intranasally inoculated influenza a virus in mice. Vet Pathol. 2004; 41(2):101–107.
   PubMed Web of Science ®Google Scholar
• Netland J, Meyerholz DK, Moore S, et al. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol. 2008; 82(15):7264–7275.
   PubMed Web of Science ®Google Scholar
• Khan S, Ali A, Siddique R, et al. Novel coronavirus is putting the whole world on alert. J Hosp Infect. 2020; 104(3):252–253.
   PubMed Web of Science ®Google Scholar
• Sankowski R, Mader S, Valdés-Ferrer SI. Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration. Front Cell Neurosci. 2015;9:28.
   PubMed Web of Science ®Google Scholar
• Napoli PE, Nioi M, d’Aloja E, et al. The ocular surface and the Coronavirus Disease 2019: Does a dual ‘ocular route’ exist? J Clin Med. 2020; 9(5):1269.
   Web of Science ®Google Scholar
• Olofsson S, Kumlin U, Dimock K, et al. Avian influenza and sialic acid receptors: More than meets the eye? Lancet Infect Dis. 2005; 5(3):184–188.
   PubMed Web of Science ®Google Scholar
• Xia J, Tong J, Liu M, et al. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS‐CoV‐2 infection. J Med Virol. 2020; 92(6):589–594.
   Web of Science ®Google Scholar
• Zhou Y, Zeng Y, Tong Y, et al. Ophthalmologic evidence against the interpersonal transmission of 2019 novel coronavirus through conjunctiva. MedRxiv. 2020;
   Google Scholar
• Lu C-W, Liu X-F, Jia Z-F. 2019-nCoV transmission through the ocular surface must not be ignored. Lancet. 2020;395(10224):e39.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020; 97(5):829–838.
   PubMed Web of Science ®Google Scholar
• Li Z, Wu M, Yao J, et al. Caution on kidney dysfunctions of COVID-19 patients. 2020; 2020.02.08.20021212.
   Google Scholar
• Fan C, Li K, Ding Y, et al. ACE2 expression in kidney and testis may cause kidney and testis damage after 2019-nCoV infection. 2020; 2020.02.12.20022418.
   Google Scholar
• Xu J, Qi L, Chi X, et al. Orchitis: a complication of severe acute respiratory syndrome (SARS). Biol Reprod. 2006; 74(2):410–416.
   PubMed Web of Science ®Google Scholar
• Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). Jama. 2016; 315(8):801–810.
   PubMed Web of Science ®Google Scholar
• Ferreira FL, Bota DP, Bross A, et al. Serial evaluation of the SOFA score to predict outcome in critically ill patients. Jama. 2001; 286(14):1754–1758.
   PubMed Web of Science ®Google Scholar
• Zhou F, Wang Y, Liu Y, et al. Disease severity and clinical outcomes of community-acquired pneumonia caused by non-influenza respiratory viruses in adults: A multicentre prospective registry study from the CAP-China Network. Eur Respir J. 2019; 54(2):1802406.
   PubMed Web of Science ®Google Scholar
• He L, Ding Y, Zhang Q, et al. Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: Relation to the acute lung injury and pathogenesis of SARS. J Pathol. 2006; 210(3):288–297.
   PubMed Web of Science ®Google Scholar
• Chen J, Subbarao K. The immunobiology of SARS. Annu Rev Immunol. 2007;25(1):443–472.
   PubMedGoogle Scholar
• Law HK, Cheung CY, Ng HY, et al. Chemokine up-regulation in sars-coronavirus–infected, monocyte-derived human dendritic cells. Blood. 2005; 106(7):2366–2374.
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Hill T, Li K, et al. Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells. J Virol. 2009; 83(7):3039–3048.
   PubMed Web of Science ®Google Scholar
• Xu X, Gao X-M. Immunological responses against SARS-coronavirus infection in humans. Cell Mol Immunol. 2004;1(2):119–122.
   PubMed Web of Science ®Google Scholar
• Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol. 2020; 92(4):424–432.
   PubMed Web of Science ®Google Scholar
• To KF, Chan PKS, Chan K-F, et al. Pathology of fatal human infection associated with avian influenza A H5N1 virus. J Med Virol. 2001; 63(3):242–246.
   PubMed Web of Science ®Google Scholar
• Haanen JB, Cerundolo V. NKG2A, a new kid on the immune checkpoint block. Cell. 2018;175(7):1720–1722.
   PubMed Web of Science ®Google Scholar
• Diao B, Wang C, Tan Y, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020;11: 827
   Google Scholar
• Yang M, Cell pyroptosis, a potential pathogenic mechanism of 2019-nCoV infection. Available at SSRN 3527420, 2020.
   Google Scholar
• Hirano T, Murakami M. COVID-19: A new virus, but a familiar receptor and cytokine release syndrome. Immunity. 2020;52(5):731–733.
   PubMed Web of Science ®Google Scholar
• Liu L, Wei Q, Lin Q, et al. Anti–spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. 2019; 4(4): DOI:10.1172/jci.insight.123158
   Web of Science ®Google Scholar
• Vivier E, Artis D, Colonna M, et al. Innate lymphoid cells: 10 years on. Cell. 2018; 174(5):1054–1066.
   PubMed Web of Science ®Google Scholar
• Wang Y, Lifshitz L, Gellatly K, et al. HIV-1-induced cytokines deplete homeostatic innate lymphoid cells and expand TCF7-dependent memory NK cells. Nat Immunol. 2020; 21(3):274–286.
   PubMed Web of Science ®Google Scholar
• Cao Q, Wang R, Wang Y, et al. Regulatory innate lymphoid cells suppress innate immunity and reduce renal ischemia/reperfusion injury. Kidney Int. 2020; 97(1):130–142.
   PubMed Web of Science ®Google Scholar
• Satoh-Takayama N, Kato T, Motomura Y, et al. Bacteria-induced group 2 innate lymphoid cells in the stomach provide immune protection through induction of IgA. Immunity. 2020; 52(4):635–649.e4.
   PubMed Web of Science ®Google Scholar
• Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: a review. Clin Immunol. 2020;215:108427.
   PubMed Web of Science ®Google Scholar
• Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):e343.
   PubMed Web of Science ®Google Scholar
• Arabi YM, Shalhoub S, Mandourah Y, et al. Ribavirin and interferon therapy for critically ill patients with middle east respiratory syndrome: A multicenter observational study. Clinl Infect Dis. 2020;70(9):1837–1844
   PubMed Web of Science ®Google Scholar
• Falzarano D, De Wit E, Rasmussen AL, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques. Nat Med. 2013; 19(10):1313–1317.
   PubMed Web of Science ®Google Scholar
• Omrani AS, Saad MM, Baig K, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: A retrospective cohort study. Lancet Infect Dis. 2014; 14(11):1090–1095.
   PubMed Web of Science ®Google Scholar
• Cao X. COVID-19: Immunopathology and its implications for therapy. Nat Rev Immunol. 2020;20(1):1–2.
   PubMedGoogle Scholar
• Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020; 382(19):1787–1799.
   PubMed Web of Science ®Google Scholar
• Meneguzzo F, Ciriminna R, Zabini F, et al. Hydrodynamic cavitation-based rapid expansion of hesperidin-rich products from waste citrus peel as a potential tool against COVID-19. 2020;
   Google Scholar
• Arabi Y, Shalhoub S, Mandourah Y, et al. Ribavirin and interferon therapy for critically ill patients with middle east respiratory syndrome: A multicenter observational study. Clin Infect Dis. 2019; 70:1837–1844.
   Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269–271.
   Web of Science ®Google Scholar
• Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.
   PubMed Web of Science ®Google Scholar
• Davidson S, Maini MK, Wack A. Disease-promoting effects of type I interferons in viral, bacterial, and coinfections. J Interferon Cytokine Res. 2015;35(4):252–264.
   PubMed Web of Science ®Google Scholar
• Deng X, Yu X, Pei J. Regulation of interferon production as a potential strategy for COVID-19 treatment. arXiv Preprint arXiv. 2020; 2003.00751
   Google Scholar
• Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: Reanalysis of a prior phase III trial. Crit Care Med. 2016; 44(2):275–281.
   PubMed Web of Science ®Google Scholar
• Jie Z, He H, Xi H, et al. Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Expert Consensus on Chloroquine Phosphate for the Treatment of Novel Coronavirus Pneumonia [in Chinese] 2020; 10:1001–0939.2020
   Google Scholar
• Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020; 395(10223):e30–e31.
   PubMed Web of Science ®Google Scholar
• Stebbing J, Phelan A, Griffin I, et al. COVID-19: Combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020; 20(4):400–402.
   PubMed Web of Science ®Google Scholar